 Carcinomatous meningitis antibody-guided therapy Seven patients carcinomatous meningitis intrathecal monoclonal antibody Clinical responses patients long term survivor months Aseptic meningitis patients serious toxicity form seizures patients myelosuppression patients Partial obliteration subarachnoid space potential problem patients advanced disease